The Europe Wearable Injectors Market would witness market growth of 9.0% CAGR during the forecast period (2022-2028).
Interaction between wearable devices and digital health platforms is also improved by wearable devices. Additional electronics can be integrated into the architecture of these items, providing an unprecedented level of digital control and monitoring. The patient can modify the volume of delivery or flow rate through connected applications on the basis of their preferences or recommendations by physician. In the event of diabetes, the devices can even communicate with other external devices, such as glucose meters, to continuously monitor glucose levels and changes the insulin delivery strategy. These closed-loop systems are a huge step forward in the use of machine intelligence to assist patients. In many circumstances, increasing treatment transparency can improve patient outcomes by allowing clinicians to detect possible problems before they develop.
There are numerous favorable trends in the burden of chronic disease in Europe, but there are also some major difficulties. On the one hand, there has been a significant and continuous decrease in mortality, notably among the young and middle-aged, resulting in a significant increase in life expectancy in all 28 EU countries (EU28) over the last 40 years. According to the National Library of Medicine, even within the fairly recent period of 2003–2013, life expectancy in the EU increased by 3.2 years for males and 2.5 years for women. While these trends reflect a huge public health achievement, they also conceal less positive developments, such as significant health inequities. There are significant disparities in life expectancy across Europe, with men living longer than women. The distinctions between southern Mediterranean Europe and central Europe and the Baltic region are the most apparent. However, this increase in life expectancy is not all healthy life expectancy. In Europe, for example, a man and a woman in their 65th year would have a life expectancy of 18 and 21 years, respectively. Only 9 of these years will be spent in good health. The rest are characterized by age-related morbidity caused by one or more chronic diseases (multimorbidity), leading to a significant decrease in quality of life and an increase in healthcare spending.
The Germany market dominated the Europe Wearable Injectors Market by Country 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $841.7 Million by 2028. The UK market is experiencing a CAGR of 8.1% during (2022 - 2028). Additionally, The France market would display a CAGR of 9.8% during (2022 - 2028).
Based on Therapy, the market is segmented into Diabetes, Cardiovascular disease, Immuno-oncology, and Others. Based on End User, the market is segmented into Hospitals & Clinics and Home healthcare setting. Based on Type, the market is segmented into On-body Injector and Off-body Injector. Based on Technology, the market is segmented into Spring Based, Motor Based, Rotary pump, Expanding battery, and others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Wearable Injectors Market will Hit $12.9 Billion by 2028, at a CAGR of 9.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Insulet Corporation, United Therapeutics Corporation, ATS Automation Tooling Systems, Inc., Ypsomed AG, Amgen, Inc., West Pharmaceutical Services, Inc., Zealand Pharma A/S (Valeritas, Inc.), Medtronic PLC, CeQur SA, and Subcuject ApS.
By Therapy
By End User
By Type
By Technology
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
